Thiazolidinediones are associated with a reduced risk of COPD exacerbations

References

• ManninoDMBuistASGlobal burden of COPD: risk factors, prevalence, and future trendsLancet2007370958976577317765526
   PubMed Web of Science ®Google Scholar
• MininoAMMurphySLXuJKochanekKDDeaths: final data for 2008Natl Vital Stat Rep201159101126
   Google Scholar
• LopezADShibuyaKRaoCChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J200627239741216452599
   PubMed Web of Science ®Google Scholar
• FosterTSMillerJDMartonJPCaloyerasJPRussellMWMenzinJAssessment of the economic burden of COPD in the U.S.: a review and synthesis of the literatureCOPD20063421121817361502
   PubMedGoogle Scholar
• ToyELGallagherKFStanleyELSwensenARDuhMSThe economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a reviewCOPD20107321422820486821
   PubMedGoogle Scholar
• PapiALuppiFFrancoFFabbriLMPathophysiology of exacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc20063324525116636093
   PubMedGoogle Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• RemelsAHGoskerHRSchrauwenPLangenRCScholsAMPeroxisome proliferator-activated receptors: a therapeutic target in COPD?Eur Respir J200831350250818310397
   PubMed Web of Science ®Google Scholar
• SpiegelmanBMPPAR-gamma: adipogenic regulator and thiazolidinedione receptorDiabetes19984745075149568680
   PubMed Web of Science ®Google Scholar
• SpearsMMcSharryCThomsonNCPeroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary diseaseClin Exp Allergy200636121494150417177672
   PubMed Web of Science ®Google Scholar
• PatelHJBelvisiMGBishop-BaileyDYacoubMHMitchellJAActivation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapyJ Immunol200317052663266912594295
   PubMed Web of Science ®Google Scholar
• RinneSTFeemsterLCCollinsBFThiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort studyAllergy Asthma Clin Immunol20141013425024717
   PubMed Web of Science ®Google Scholar
• CookeCRJooMJAndersonSMThe validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary diseaseBMC Health Serv Res2011113721324188
   PubMed Web of Science ®Google Scholar
• ZekiAASchivoMChanAAlbertsonTELouieSThe asthma-COPD overlap syndrome: a common clinical problem in the elderlyJ Allergy (Cairo)2011201186192622121384
   PubMedGoogle Scholar
• SuissaSImmortal time bias in pharmaco-epidemiologyAm J Epidemiol2008167449249918056625
   PubMed Web of Science ®Google Scholar
• JoishVNMaloneDCWendelCDraugalisJRMohlerMJDevelopment and validation of a diabetes mellitus severity index: a risk-adjustment tool for predicting health care resource use and costsPharmacotherapy200525567668415899729
   PubMed Web of Science ®Google Scholar
• AshASEllisRPPopeGCUsing diagnoses to describe populations and predict costsHealth Care Financ Rev200021372811481769
   PubMed Web of Science ®Google Scholar
• DendalePDe KeulenaerGTroisfontainesPEffect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) studyEur J Heart Fail201214333334022045925
   PubMed Web of Science ®Google Scholar
• StataCorpStata Statistical Software: Release 112College Station, TXStataCorp LP2012
   Google Scholar
• BrysonCLAuDHYoungBMcDonellMBFihnSDA refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp)Med Care200745649750417515776
   PubMed Web of Science ®Google Scholar
• SinDDMcAlisterFAManSFAnthonisenNRContemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA2003290172301231214600189
   PubMed Web of Science ®Google Scholar
• ThompsonABMuellerMBHeiresAJAerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammationAm Rev Respir Dis199214623893951489129
   PubMed Web of Science ®Google Scholar
• AgarwalRAggarwalANGuptaDJindalSKInhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trialsChest2010137231832519783669
   PubMed Web of Science ®Google Scholar
• EvansRMThe steroid and thyroid hormone receptor superfamilyScience198824048548898953283939
   PubMed Web of Science ®Google Scholar
• BlanquartCBarbierOFruchartJCStaelsBGlineurCPeroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammationJ Steroid Biochem Mol Biol2003852–526727312943712
   PubMed Web of Science ®Google Scholar
• BraissantOFoufelleFScottoCDaucaMWahliWDifferential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult ratEndocrinology199613713543668536636
   PubMed Web of Science ®Google Scholar
• JiangCTingATSeedBPPAR-gamma agonists inhibit production of monocyte inflammatory cytokinesNature1998391666282869422509
   PubMed Web of Science ®Google Scholar
• WangACDaiXLuuBConradDJPeroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activationAm J Respir Cell Mol Biol200124668869311415933
   PubMed Web of Science ®Google Scholar
• ZhuMFlyntLGhoshSAnti-inflammatory effects of thiazolidinediones in human airway smooth muscle cellsAm J Respir Cell Mol Biol201145111111920870897
   PubMed Web of Science ®Google Scholar
• RichardsDBBareillePLindoELQuinnDFarrowSNTreatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trialRespir Med2010104566867419944580
   PubMed Web of Science ®Google Scholar
• SpearsMDonnellyIJollyLBronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthmaClin Pharmacol Ther2009861495319357642
   PubMed Web of Science ®Google Scholar
• CaoCWangRWangJBunjhooHXuYXiongWBody mass index and mortality in chronic obstructive pulmonary disease: a meta-analysisPLoS One201278e4389222937118
   PubMed Web of Science ®Google Scholar
• GuanYHaoCChaDRThiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorptionNat Med200511886186616007095
   PubMed Web of Science ®Google Scholar
• NestoRWBellDBonowROThiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003Circulation2003108232941294814662691
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• DrummondMBHanselNNConnettJEScanlonPDTashkinDPWiseRASpirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012185121301130622561963
   PubMed Web of Science ®Google Scholar